Genmab AS (MEX:GMABN) Construction In Progress: MXN0 Mil (As of Mar. 2026)


MEX:GMABN Genmab AS MEX:GMABN
92 GF Score
Price MXN4,027.79
GF Value MXN5,328.99
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Construction In Progress?

Genmab AS MEX:GMABN 92 Construction In Progress is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:GMABN with a GF Score™ of 92/100 and a GF Value™ of MXN5,328.99 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Genmab AS's quarterly construction in progress increased from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN54 Mil) but then declined from Dec. 2025 (MXN54 Mil) to Mar. 2026 (MXN0 Mil).

Genmab AS's annual construction in progress increased from Dec. 2023 (MXN102 Mil) to Dec. 2024 (MXN292 Mil) but then declined from Dec. 2024 (MXN292 Mil) to Dec. 2025 (MXN54 Mil).

Genmab AS Construction In Progress Historical Data

* Premium members only.

The historical data trend for Genmab AS's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Construction In Progress Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 162.39 653.80 101.85 291.98 54.02

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 54.02 0.00
MEX:GMABN
92GF Score
Genmab AS MEX:GMABN
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of MXN0 Mil mean?
Genmab AS (MEX:GMABN) has a Construction In Progress of MXN0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Genmab AS and its competitors.
Is Genmab AS's Construction In Progress too high?
Genmab AS's current Construction In Progress is MXN0 Mil. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Construction In Progress compare to VRTX and REGN?
Genmab AS's Construction In Progress of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Genmab AS and its competitors. Genmab AS's current Construction In Progress is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current Construction In Progress is MXN0 Mil. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Construction In Progress is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (MEX:GMABN) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for MEX:GMABN:

  • Construction In Progress: MXN0 Mil
  • GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score

Get the complete analysis for MEX:GMABN

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,027.79
Price
MXN5,328.99
GF Value